Stockreport

Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra

Catalyst Biosciences, Inc.  (CBIO) 
Last catalyst biosciences, inc. earnings: 11/7 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: catalystbiosciences.com/investors
PDF SOUTH SAN FRANCISCO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase [Read more]